Novartis leukemia drug gets US approval
Novartis said that it will supply Tasigna throughout the US within days following this approval to meet the treatment needs of these patients with Philadelphia chromosome-positive (Ph+) chronic
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.
Dalton Medicinal Chemistry Partners is utilizing its medicinal chemistry expertise to design and synthesize novel compounds against an antiviral target selected by Boehringer Ingelheim (Canada). Peter Pekos, president